The economic impact of opportunistic PSA screening: a real-world cost analysis from China amid evolving policy landscape.

Authors

Zhehan Lin, Wei Li, Pengcheng Hu, Chunlei Liu, Yizhen Wang, Shen Wang, Xiaopeng Lan

Published in

Expert review of pharmacoeconomics & outcomes research. Pages 1-8. Aug 17, 2026. Epub Aug 17, 2026.

Abstract

The clinical value of prostate-specific antigen (PSA) screening remains debated, and health economic evidence from real-world Chinese screening programs is lacking. This study aimed to determine whether PSA screening reduces prostate cancer treatment costs in China.
Using propensity score matching within a policy-driven community screening initiative in China, 61 screening-detected prostate cancer patients were matched with 61 symptom-detected controls. All patients were diagnosed and treated at the same central hospital. Total direct medical costs (including examination, hospitalization, surgery, chemotherapy, and radiotherapy) were compared between the two groups.
Screening-detected patients incurred significantly lower mean treatment costs than controls (107,609 CNY vs. 193,746 CNY; p = 0.0163), representing a 44% reduction.
This first direct economic evidence from China suggests that PSA screening is associated with substantially reduced treatment costs, likely attributable to earlier diagnosis and less intensive treatment. These findings support the economic case for considering organized PSA screening as a preventive health measure in China. Further multicenter studies with longer follow-up are warranted to confirm these results.

PMID:
42606097
Bibliographic data and abstract were imported from PubMed on 17 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.